Document Type
Article
Publication Title
Journal of immunotherapy and precision oncology
Abstract
INTRODUCTION: Targeted therapies and immune checkpoint inhibitors (ICIs) have revolutionized the management of metastatic non-small cell lung cancer (NSCLC) over the past decade.
METHODS: This single-center observational study was conducted to describe programmed death-ligand 1 (PD-L1) testing, choice of therapy, and outcomes for adult patients with stage IV NSCLC initiating first-line therapy from 2017 through 2020, with follow-up through June 2021. Patient characteristics and study assessments were described according to four histomolecular subtypes, defined by histologic characteristics and availability of standard-of-care therapies for molecular subgroups at the time of study conduct.
RESULTS: Of 507 eligible patients with metastatic NSCLC, 85 (17%) had squamous NSCLC; 288 (57%) had nonsquamous NSCLC with no actionable genomic alteration; 44 (9%) had nonsquamous NSCLC with
CONCLUSION: Study findings highlight the increased use of PD-L1 testing over the years from 2017 to 2020 and recent changes in therapy, with decreased use of chemotherapy and increased use of ICI-chemotherapy combinations during the study in each histomolecular group. Moreover, we observed improvements in survival for patients with metastatic NSCLC relative to historical real-world data.
First Page
161
Last Page
171
DOI
10.36401/JIPO-24-26
Publication Date
5-1-2025
Recommended Citation
Altan M, Sui D, Xu C, Simon GR, Sulihem ST, Malveaux D, Ponce D, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Zhang J, Gibbons DL, Vaporciyan AA, Heymach JV, Santorelli ML, Burke T, Williams LA. PD-L1 Testing, Treatment Patterns, and Clinical Outcomes Among Patients with Metastatic NSCLC at an Academic Medical Center, 2017-2021. J Immunother Precis Oncol. 2025 Apr 14;8(2):161-171. doi: 10.36401/JIPO-24-26. PMID: 40235643; PMCID: PMC11998521.